19 research outputs found
Muon `Depth -- Intensity' Relation Measured by LVD Underground Experiment and Cosmic-Ray Muon Spectrum at Sea Level
We present the analysis of the muon events with all muon multiplicities
collected during 21804 hours of operation of the first LVD tower. The measured
angular distribution of muon intensity has been converted to the `depth --
vertical intensity' relation in the depth range from 3 to 12 km w.e.. The
analysis of this relation allowed to derive the power index, , of the
primary all-nucleon spectrum: . The `depth -- vertical
intensity' relation has been converted to standard rock and the comparison with
the data of other experiments has been done. We present also the derived
vertical muon spectrum at sea level.Comment: 7 pages, 3 figures, to be published on Phys. Rev.
Upper Limit on the Prompt Muon Flux Derived from the LVD Underground Experiment
We present the analysis of the muon events with all muon multiplicities
collected during 21804 hours of operation of the first LVD tower. The measured
depth-angular distribution of muon intensities has been used to obtain the
normalization factor, A, the power index, gamma, of the primary all-nucleon
spectrum and the ratio, R_c, of prompt muon flux to that of pi-mesons - the
main parameters which determine the spectrum of cosmic ray muons at the sea
level. The value of gamma = 2.77 +/- 0.05 (68% C.L.) and R_c < 2.0 x 10^-3 (95%
C.L.) have been obtained. The upper limit to the prompt muon flux favours the
models of charm production based on QGSM and the dual parton model.Comment: 10 pages, 4 figures, RevTex. To appear in Phys. Rev.
Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)
Background: This study provides a global overview of the management of patients with acute cholecystitis during the initial phase of the COVID-19 pandemic. Methods: CHOLECOVID is an international, multicentre, observational comparative study of patients admitted to hospital with acute cholecystitis during the COVID-19 pandemic. Data on management were collected for a 2-month study interval coincident with the WHO declaration of the SARS-CoV-2 pandemic and compared with an equivalent pre-pandemic time interval. Mediation analysis examined the influence of SARS-COV-2 infection on 30-day mortality. Results: This study collected data on 9783 patients with acute cholecystitis admitted to 247 hospitals across the world. The pandemic was associated with reduced availability of surgical workforce and operating facilities globally, a significant shift to worse severity of disease, and increased use of conservative management. There was a reduction (both absolute and proportionate) in the number of patients undergoing cholecystectomy from 3095 patients (56.2 per cent) pre-pandemic to 1998 patients (46.2 per cent) during the pandemic but there was no difference in 30-day all-cause mortality after cholecystectomy comparing the pre-pandemic interval with the pandemic (13 patients (0.4 per cent) pre-pandemic to 13 patients (0.6 per cent) pandemic; P = 0.355). In mediation analysis, an admission with acute cholecystitis during the pandemic was associated with a non-significant increased risk of death (OR 1.29, 95 per cent c.i. 0.93 to 1.79, P = 0.121). Conclusion: CHOLECOVID provides a unique overview of the treatment of patients with cholecystitis across the globe during the first months of the SARS-CoV-2 pandemic. The study highlights the need for system resilience in retention of elective surgical activity. Cholecystectomy was associated with a low risk of mortality and deferral of treatment results in an increase in avoidable morbidity that represents the non-COVID cost of this pandemic